


PlexPCR[®] SARS-CoV-2

Dual target COVID-19 test

Scalable solution supporting surge capacity



Simple workflow, seamless integration

- ▶ High-throughput, compatible with 384-well and liquid handling instrumentation to accelerate time to result
- ▶ Supply chain security for high-volume testing based on unique probe chemistry technology
- ▶ Detect known circulating variants* with confidence - conserved dual target (RdRp/ORF1ab) design for high specificity and sensitivity

PlexPCR® SARS-CoV-2 is a dual-target, single-well, multiplex reverse transcription qPCR test for the detection of COVID-19 causative coronavirus (SARS-CoV-2) plus RNA internal control.¹

Test with confidence

- ▶ Two-target design focused on non-variable gene targets *ORF1ab* and *RdRp*, plus RNA-based Internal Control
- ▶ Conserved gene regions for excellent specificity and clinical sensitivity,* unaffected by spike protein mutations and other known variants
- ▶ Full process control monitors extraction performance, RT-step and amplification for full confidence in results

SpeedX Analysis software

- ▶ Automate data processing and results interpretation for large numbers of samples simultaneously
- ▶ Speed up results processing and spend your time only on the few samples that require attention
- ▶ Automated plate set-up options for a streamlined workflow
- ▶ High security and GDPR compliant with LIS compatibility

Powered by proprietary **PlexPCR®** technology demonstrating improved multiplex performance compared with other probe-based tests.²

Well	Channel	Target
1	1	ORF1ab
	2	RdRp
	3	RNA Internal Control

Validated with nasopharyngeal swab specimens.¹

Demonstrated clinical performance¹

Clinical evaluation of PlexPCR® SARS-CoV-2 (n=142)	
Positive Percent Agreement	93.26% (95% CI 85.90 - 97.49%)
Negative Percent Agreement	96.23% (95% CI 87.02 - 99.54%)
Overall Rate of Agreement	94.37% (95% CI 89.20 - 97.54%)

Composite reference result from Abbott m2000 SARS-CoV-2 assay & BGI real-time fluorescent RT-PCR Kit for detection of SARS-CoV-2.¹

Streamline your Respiratory testing **PlexPCR® SARS-CoV-2** plus **PlexPCR® RespiVirus**

PlexPCR® SARS-CoV-2 workflow is compatible with **PlexPCR® RespiVirus** for a comprehensive Respiratory virus testing solution. A single extraction, combined amplification and automated analysis workflow, utilising just 3 wells for 12 results.

Product	Compatible	Size	Cat#
PlexPCR® SARS-CoV-2*	LC480 II / CFX	384 reactions [†]	1301384
Related Products	Compatible	Size	Cat#
PlexPCR® RespiVirus	LC480 II	100 reactions 192 reactions [†]	1201001 1201192
PlexPCR® Colour Compensation	LC480 II	2 reactions	90001

* Based on *in silico* investigation as of April 2026. Contact tech@speedx.com.au for up-to-date QAP data

[†] Additional volumes provided for use with liquid handling systems

Available only in Australia and New Zealand.

References: 1. **PlexPCR® SARS-CoV-2** Instructions for use 2. Tan LY *et al*, PLOS ONE. 2017; 12(1): e0170087

PlexPCR® SARS-CoV-2 and **RespiVirus** kits are developed and manufactured by **SpeedX Pty Ltd**, Sydney. **PlexPCR®** & **SpeedX®** are registered trademarks of **SpeedX Pty Ltd**. Other copyright and trademarks are the property of the respective owners. **SpeedX Pty Ltd**, products may be covered by one or more local or foreign patents. Visit www.speedxpcr.com/patents for comprehensive patent information.

Australia — **SpeedX Pty. Ltd.**

+61 (0)2 9209 4170

sales@speedx.com.au

Find out more **speedxpcr.com**

